法国生物技术公司Lys Therapeutics筹集超过2500万欧元融资，推动 LYS241在神经学领域的临床开发-动脉网

Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology

CISION 等信源发布 2026-06-22 23:12



可切换为仅中文







Financing includes a grant of more than $5 million from The Michael J. Fox Foundation to advance a first-in-class neurovascular antibody across major neurological indications

融资包括来自迈克尔·J·福克斯基金会的一笔超过500万美元的资助，用于推动一种首创的神经血管抗体在主要神经系统适应症中的研发。

LYON and CAEN, France

法国里昂和卡昂

，

June 22, 2026

2026年6月22日

/PRNewswire/ -- Lys Therapeutics, a French biotechnology company pioneering a novel approach targeting the tPA-NMDAr axis in neurodegenerative and neurovascular diseases, today announced that it has raised more than €25 million since its founding in 2021. Over the past five years, the company has achieved key preclinical, regulatory, manufacturing and translational milestones, positioning its lead candidate, LYS241, for clinical development..

/美通社/ -- 法国生物科技公司 Lys Therapeutics 致力于开创一种针对神经退行性疾病和神经血管疾病中 tPA-NMDAr 轴的新颖疗法，该公司今日宣布，自 2021 年成立以来，已筹集超过 2,500 万欧元。在过去五年中，该公司在临床前研究、监管审批、生产制造及转化医学方面取得了关键里程碑进展，为其领先候选药物 LYS241 的临床开发奠定了基础。

LYS241 is a fully humanized, Fc-silent IgG1 monoclonal antibody designed to selectively block the pathological interaction between tissue plasminogen activator (tPA) and NMDA receptors (NMDAr), while preserving physiological receptor function. By targeting this neurovascular pathway, LYS241 is intended to address mechanisms associated with blood-brain barrier dysfunction, neuroinflammation and excitotoxicity across Parkinson's disease, synucleinopathies including multiple system atrophy, and ischemic stroke..

LYS241 是一种全人源化、Fc 静默的 IgG1 单克隆抗体，旨在选择性阻断组织型纤溶酶原激活物（tPA）与 NMDA 受体（NMDAr）之间的病理性相互作用，同时保留受体的生理功能。通过靶向这一神经血管通路，LYS241 旨在解决与血脑屏障功能障碍、神经炎症和兴奋性毒性相关的机制，适用于帕金森病、包括多系统萎缩在内的突触核蛋白病以及缺血性卒中。

The financing includes a grant of more than $5 million from The Michael J. Fox Foundation for Parkinson's Research, as well as support from Bpifrance, France 2030 and private investors.

该融资包括来自迈克尔·J·福克斯帕金森病研究基金会的一笔超过500万美元的拨款，以及来自法国公共投资银行（Bpifrance）、“法国2030”计划和私人投资者的支持。

The proceeds will support completion of regulatory studies, manufacturing readiness and the clinical entry of LYS241 through a biomarker-rich Phase 1a/1b program. The planned program is expected to include healthy volunteer cohorts and indication-specific patient cohorts designed to assess safety, pharmacokinetics and early proof-of-biology signals across priority neurological indications..

所得资金将用于支持监管研究的完成、生产准备以及通过一项富含生物标志物的 Phase 1a/1b 计划推动 LYS241 进入临床试验。该计划预计包括健康志愿者队列和针对特定适应症患者设计的队列，以评估在优先神经适应症中的安全性、药代动力学及早期生物学效应信号。

Recent preclinical data support the potential of LYS241 to address BBB dysfunction, neuroinflammation and neurodegenerative progression in Parkinson's disease. In synucleinopathies, including multiple system atrophy, additional preclinical data further support the relevance of the approach. In ischemic stroke, LYS241 is being developed as a standalone or adjunctive therapy to standard reperfusion strategies, with the goal of improving reperfusion quality and reducing hemorrhagic and inflammatory complications..

最近的临床前数据支持LYS241在解决帕金森病中的血脑屏障功能障碍、神经炎症和神经退行性进展方面的潜力。在包括多系统萎缩在内的突触核蛋白病中，额外的临床前数据进一步支持该方法的相关性。在缺血性卒中方面，LYS241正被开发为一种独立或辅助标准再灌注策略的疗法，旨在提高再灌注质量并减少出血性和炎症性并发症。

'Raising more than €25 million in five years reflects strong confidence in our science, our execution and the broad therapeutic potential of LYS241,' said Dr. Manuel Blanc, CEO and co-founder of Lys Therapeutics. 'This support enables us to complete the work required for clinical entry and pursue our ambition of translating a differentiated understanding of neurovascular biology into a new class of disease-modifying therapies for severe neurological disorders with substantial unmet medical needs.'.

“在五年内筹集超过2,500万欧元，反映了市场对我们科学基础、执行能力以及LYS241广泛治疗潜力的高度信心，”Lys Therapeutics首席执行官兼联合创始人Manuel Blanc博士表示。“这一支持使我们能够完成进入临床试验所需的工作，并推动我们将对神经血管生物学的差异化理解转化为针对存在巨大未满足医疗需求的严重神经系统疾病的一类新型疾病修饰疗法。”

For more information:

更多信息：

lys-tx.com

Full press-release:

完整新闻稿：

https://bit.ly/4uMYiU0

Contact:

联系方式：

[email protected]

Logo -

标志 -

https://mma.prnewswire.com/media/2998132/Lys_Therapeutics_Logo.jpg